The association between ADHD and car crash risk among older adult drivers.
Ocugen plans Phase I/II trials for macular disease gene therapies – Pharmaceutical Technology
Ocugen announced that the manufacturing facility for its regenerative cell therapy for cartilage, NeoCart, is expected for completion by the end of 2023. Image Credit: